Santé log

Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

AN4035 is a proprietary CEACAM5-targeting antibody drug conjugate (ADC) designed to deliver potent anti-tumor activity with an improved therapeutic window. It is armed with Adlai Nortye’s ...
Santé log

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie

Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie ...
Santé log

Ipsen annonce son intention d’acquérir ImCheck Therapeutics et étend son leadership en oncologie avec un portefeuille enrichi de produits en R&D

Ipsen va acquérir toutes les actions émises et en circulation d'ImCheck Therapeutics, pour lesquelles les actionnaires d'ImCheck Therapeutics auront droit à un prix d'achat final de 350 millions et à ...
Santé log

ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Development of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections

ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, announces today that it has ...
Santé log

Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance

Year-to-date total sales growth of 12.1% at CER 1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline® Further upgrade of ...
Santé log

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)

Novartis today announced that Cosentyx® (secukinumab) met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial 1. Cosentyx demonstrated statistically significant and ...
Santé log

Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'année 2025 et revoit à la hausse ses prévisions pour l'exercice en cours

Croissance du chiffre d’affaires d’environ 10,0 % (objectif précédent : supérieure à 7,0%), à taux de change constant. Sur la base des taux de change moyens en septembre 2025, Ipsen anticipe un impact ...
Santé log

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer

Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis’ previously ...
Santé log

Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline

Ipsen to acquire all issued and outstanding shares of ImCheck Therapeutics, for which ImCheck Therapeutics’ shareholders will be eligible to receive a closing purchase price of 350 million euros and ...
Santé log

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

Leerink Partners, TD Cowen, Guggenheim Securities, Wells Fargo Securities and LifeSci Capital are acting as joint bookrunning managers for the offering. H.C. Wainwright & Co. and Clear Street are ...
Santé log

Aveanna Announces Pricing of Secondary Offering of Common Stock

Jefferies and J.P. Morgan are acting as joint lead book-running managers for the Offering. Barclays and RBC Capital Markets are acting as book-running managers for the Offering. BMO Capital Markets, ...
Santé log

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

SAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in Citi’s ...